This Specialized Program of Research Excellence (SPORE) in Brain Cancer at Mayo Clinic Cancer Center will support a multidisciplinary team of basic, clinical, and population science investigators to perform translational research directed at significantly reducing morbidity and mortality from brain cancer. Brian Patrick O'Neill, MD will serve as Overall Principal Investigator and Director of the Administrative Core. Robert B. Jenkins, MD, PhD, will serve as Overall Co-Principal Investigator and Administrative Core Co-Director. The SPORE will serve as the organizational nucleus for the research activities in these areas. The translational research objectives of the SPORE will be directed by 13 investigators from 8 departments with a demonstrable history of collaborative and translational research. The SPORE comprises four Mayo investigator-initiated research projects, and four core resources constructed around a theme of adult gliomas and consolidated by an Administrative Core. The SPORE also comprises Career Development and Developmental Research Programs. SPORE Research Projects: 1. Optimizing EGFR Inhibitor-based Therapies in Glioblastoma 2. Targeted MV-CEA as a Potent Antitumor Agent against Glioblastoma 3. Souble EGFR as a Potential Biomarker in Malignant Gliomas 4. Association of Chromosome 19 q-arm Polymorphisms with Glioma Development, Survival, and Response to Therapy SPORE Scientific Cores: A) Administrative B) Biostatistics C) Pathology D) Xenograft E) Clinical Research This SPORE structure provides the ideal mechanism to focus and integrate the discovery efforts of investigators and to optimally utilize the resources of the Mayo Clinic practice and the Mayo Clinic Cancer Center to conduct meaningful studies of brain cancer that will translate effectively.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Specialized Center (P50)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-GRB-V (M1))
Program Officer
Arnold, Julia T
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Mayo Clinic, Rochester
United States
Zip Code
Jung, Mi-Yeon; Kang, Jeong-Han; Hernandez, Danielle M et al. (2018) Fatty acid synthase is required for profibrotic TGF-? signaling. FASEB J 32:3803-3815
Msaouel, Pavlos; Opyrchal, Mateusz; Dispenzieri, Angela et al. (2018) Clinical Trials with Oncolytic Measles Virus: Current Status and Future Prospects. Curr Cancer Drug Targets 18:177-187
Zhou, Dan; Alver, Bonnie M; Li, Shuang et al. (2018) Distinctive epigenomes characterize glioma stem cells and their response to differentiation cues. Genome Biol 19:43
Vaubel, Rachael A; Caron, Alissa A; Yamada, Seiji et al. (2018) Recurrent copy number alterations in low-grade and anaplastic pleomorphic xanthoastrocytoma with and without BRAF V600E mutation. Brain Pathol 28:172-182
Chen, Xiaoyue; Zhang, Minjie; Gan, Haiyun et al. (2018) A novel enhancer regulates MGMT expression and promotes temozolomide resistance in glioblastoma. Nat Commun 9:2949
Nowsheen, Somaira; Aziz, Khaled; Aziz, Asef et al. (2018) L3MBTL2 orchestrates ubiquitin signalling by dictating the sequential recruitment of RNF8 and RNF168 after DNA damage. Nat Cell Biol 20:455-464
Chen, Jee-Wei E; Pedron, Sara; Shyu, Peter et al. (2018) Influence of Hyaluronic Acid Transitions in Tumor Microenvironment on Glioblastoma Malignancy and Invasive Behavior. Front Mater 5:
Youland, Ryan S; Pafundi, Deanna H; Brinkmann, Debra H et al. (2018) Prospective trial evaluating the sensitivity and specificity of 3,4-dihydroxy-6-[18F]-fluoro-L-phenylalanine (18F-DOPA) PET and MRI in patients with recurrent gliomas. J Neurooncol 137:583-591
Stathias, Vasileios; Jermakowicz, Anna M; Maloof, Marie E et al. (2018) Drug and disease signature integration identifies synergistic combinations in glioblastoma. Nat Commun 9:5315
Huff, Amanda L; Wongthida, Phonphimon; Kottke, Timothy et al. (2018) APOBEC3 Mediates Resistance to Oncolytic Viral Therapy. Mol Ther Oncolytics 11:1-13

Showing the most recent 10 out of 254 publications